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Abstract 
Background: To determine levels of Anti-
thrombin III and its prognostic value in predicting 
neonatal sepsis. 
Methods: In this descriptive study full term 
neonates (n=70)were recruited. For the diagnosis of 
neonatal sepsis 2 or more of the physical signs and 
laboratory criteria  were taken into account 
for(temperature instability< 35 or > 38.5C;tachypnea 
> 60/min; tachycardia > 200/min;capillary refill > 3 
sec; C-reactive protein level > 1 ng/ml). Neonates in 
which factors which affect the prognosis irrespective 
of disease severity of neonatal sepsis and neonates 
who presented with complications of sepsis such as, 
multiple congenital anomalies, birth weight < 2 kg, 
birth asphyxia, neonates who received prior 
treatment or presenting with complications were 
excluded. Patients with Anti-thrombin III  levels less 
than 35 UIU/dl were considered as bad prognostic 
group and those with Anti-thrombin III level 
between 50 – 75 IU/ dl were considered as good 
prognostic group .The neonates were followed for 2 
weeks. Outcomes were assessed in terms of total 
duration of hospital stay, complications developed, 
discharge or death of the neonate. p- value less than 
or equal to 0.05 was considered significant.  
Results: The mean Anti-thrombin III level in the 
good prognosis group was 53.098.8 whereas in the 
bad prognosis group was 41.6610.58 IU/dl(p <0.05). 
Anti-thrombin III level below 50 IU/dl had a 
sensitivity of 62.8%, specificity of 77.1%, positive 
predictive value of 73.3% and a negative predictive 
value of 67.5% for predicting poor prognosis and 
death. 
Conclusion: Anti-thrombin III levels can be a 
potential indicator of prognosis in neonatal sepsis.  
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Introduction 
Infection is a major cause of fatality during the first 
month of life, contributing to 13-15% of all neonatal 
deaths.1The mortality rate in neonatal sepsis may be as 
high as 50% for infants who are not treated. 2The 
incidence of culture-proven sepsis is approximately 2 
per 1000 live births. Of the 7-13 % of neonates who are 
evaluated for neonatal sepsis, only 3-8% have culture-
proven sepsis. Anti-thrombin is a potent inhibitor of 
thrombin mediated vascular injury in the micro-
circulation during severe sepsis. This endogenous 
anticoagulant is rapidly depleted in the early phases of 
sepsis as a result of decreased synthesis, increased 
destruction and enhanced clearance by Thrombin – 
Anti-thrombin complex formation. Lower initial Anti-
thrombin levels in neonatal sepsis are associated with 
a severe disease and increased mortality.3,4 It may be 
useful in predicting clinical outcome in neonatal 
sepsis. In a study conducted at Tanta University Egypt 
showed the lowest values of Anti-thrombin-III and 
protein C neonates who had died in the course of 
sepsis. The differences between survivors and non-
survivors were statistically significant.5       
Patients and Methods 
This descriptive  study was carried out at Department 
of Pediatrics, Benazir Bhutto hospital, Rawalpindi, 
from June 2010 to December 2010.  Patients(n=70)were 
recruited by consecutive (non probability) sampling. 
All term neonates of both genders admitted in NICU 
fulfilling criteria of Neonatal sepsis were included. 
Following physical signs and laboratory criteria was 
used to define sepsis; manifestation of 2 or more of the 
following physical signs that are temperature 
instability < 35 or > 38.5C, tachypnea > 60/min, 
tachycardia > 200/min, capillary refill > 3 sec and with 
a C-reactive protein level > 1 ng/ml were included. 
Neonates in which factors which affect the prognosis 
irrespective of disease severity of neonatal sepsis and 
neonates who presented with complications of sepsis 
such as, multiple congenital anomalies, birth weight < 
2 kg, birth asphyxia, neonates who received prior 
treatment or presenting with complications were 
excluded. Patients were divided into two group (35 
each) on the basis of Anti-thrombin III levels. Patients 
with Anti-thrombin III  levels less than 35 UIU/dl 
were considered as bad prognostic group and those 
with Anti-thrombin III level between 50 – 75 IU/ dl 
were considered as good prognostic group . All 
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neonates were started with the same empirical 
antibiotics and were changed according to culture and 
sensitivity report and the same supportive care and 
treatment continued. The neonates were followed for 2 
weeks. Outcomes were assessed in terms of total 
duration of hospital stay, complications developed, 
discharge or death of the neonate. For continuous 
variable like age, temperature, respiratory rate etc 
mean +S.D was presented. For categorical variables 
like, gender, discharge within 2 weeks, duration of 
hospital stay > 2 weeks and death, frequency and 
percentages were calculated. Chi square test was used 
to associate Ant-thrombin III level with neonatal sepsis 
outcome. p- value less than or equal to 0.05 was 
considered significant.  
Results 
Twenty nine (41.4%) were male babies and 41 (58.6%) 
were female babies. Mean age of the neonates was 
6.766 days with a range of 1 – 22 days. Capillary refill 
and respiratory rate revealed significant difference 
between the two groups (Table 1). 
Table 1– Baseline clinical characteristics; good 
prognosis versus bad prognosis groups 
 
Good 
prognosis* 
Bad prognosis** 
 
p-value 
Age in days 6.56.91 7.006.2 .764 
Weight in kg 2.84.461 2.981.85 .660 
Temperature (F) 101.131.22 101.281.48 .650 
Respiratory rate/ 
min 
73.8316.03 84.1710.93 
.002 
Heart rate/ min 195.1138.86 189.1135.35931 .499 
Capillary refill(secs) 3.27.74 3.911.12122 .006 
*Anti-Thrombin III =50-75 IU/dl;** Anti-Thrombin III <50 IU/dl) 
 
The neonates in the good prognosis group, all 
neonates were discharged within 2 week as opposed to 
bad prognosis neonates who stayed in the hospital for 
longer than 2 weeks. No mortality occurred in the 
good prognosis group and all neonates who died were 
included in the poor prognostic group.The mean Anti-
thrombin III level in the good prognosis group was 
53.09 IU/dl, while in bad prognostic group it was 
41.66 IU/dl) (p-value =0.00) (Table 2;Figure 1)). 
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Figure 1– Antithrombin III levels among good and bad 
prognostic groups 
Table 2– Mean Antithrombin III levels: good 
prognosis versus bad prognosis groups 
 
Prognosis N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 
p- value 
 
Good 
prognosis 
35 53.09 8.896 1.504 
 
 
0.00 
  
Bad 
prognosis 
35 41.66 10.580 1.788 
 
 Anti-Thrombin III levels showed a positive predictive 
value of 73.3% and a negative predictive value of  
67.5% (Table 3) 
Table 3- Predictive Value of Antithrombin III 
  Patients with poor 
prognosis 
(death) 
 
  Yes Yes  
Reduced 
Antithrombin 
III 
(Below 50 
IU/dl) 
Yes 
True 
Positive = 
22 
False 
Positive 
= 8 
Positive 
Predictive  
Value= 
73.3% 
No 
False 
Negative 
=13  
True  
Negati
ve= 27 
Negative 
Predictive  
Value= 
67.5% 
  
Sensitivity
= 62.8% 
Specifici
ty=77.1
% 
 
 
Discussion 
Significant proportion of neonates with good 
prognosis had antithrombin III in the good prognostic 
range . AT III is rapidly consumed during sepsis. In a 
study by Fourrier et al the results of ATIII 
measurements show that a severe initial decrease in 
ATIII level is virtually a constant feature in sepsis. 
Sequential measurements were consistent with a 
persistent decrease and a progressive spontaneous 
correction in survivors only. Initial ATIII levels had a 
very high prognostic value for prediction of death in 
their patients. 6 An acute consumption with shortening 
of the half life is the main causative mechanism of this 
ATIII decrease.7A decreased AT III hepatic synthesis 
may also be observed in chronic or acute acquired 
liver failure.8 An additional and perhaps preeminent 
mechanism in sepsis might be related to a specific 
activation of serine proteases and ATIII by elastase 
released from activated neutrophils.9, 10 Whatever the 
cause, the magnitude of the initial decrease in ATIII 
level is considered to be a reliable index of poor 
prognosis. 
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Hesselvich et al found that on the day following 
hospital admission patients with septic shock had 
lower antithrombin III and protein C levels than those 
with infection but without shock. Studies reported 
signs of more intense activation of coagulation in 
patients with septic shock as compared with those 
with infection without shock. 11 These findings were 
confirmed by Phillipe et al who also reported signs of 
more marked activation of coagulation in non 
survivors of septic shock as compared with survivors 
on the day of hospital admission. 12 In our study, non 
survivors had a more marked activation of the 
coagulation system expressed by lower antithrombin 
III levels. Only survivors showed a pattern of 
progressive normalization of antithrombin III. Other 
studies, the first determination on day 1 did not detect 
significant differences in protein C and antithrombin 
III.13 
A study conducted by Fourrier F et al showed that AT 
levels changed significantly with treatment in the 
group who recovered (P <0.01). Initial AT levels were 
significantly lower in the patient group that died 
compared to the one that recovered (P <0.01). It 
revealed that the only independent variable that had a 
significant impact was AT level (P = 0.002, OR 0.54, CI 
95%: 0.37-0.96). An increase of one unit in AT levels 
decreased the risk of mortality by a factor of 0.5. 
Specificity and sensitivity of both AT and fibrinogen 
showed a strong correlation exists between these two 
parameters. Highest sensitivity of AT with 92.3 % was 
reached at a level of 15 mg/dl. At this level, specificity, 
positive predictive value (PPV) and negative 
predictive value (NPV) were 61.9%, 60.0% and 92.8% 
respectively. Lower level of 150 mg/dl for fibrinogen 
in newborns had a sensitivity of 92.3%, specificity of 
80.9%, PPV of 25 % and NPV of 61.7% which are 
consistent with our findings. 14 
To clarify the effect of sepsis on the physiologic 
inhibition system of coagulation including protein S, 
protein C, and antithrombin III, and to study their 
further effect on thromboembolic accidents of septic 
newborns a study was conducted by Beshlawy et al. 
showed marked decrease in the level of the 
physiologic inhibition system of coagulation including 
antithrombin III, protein C, and protein S in 100% of 
cases, compared to the control group (p < .001). 15 
Antithrombin III (ATIII) has been found to be a marker 
for DIC and to be of prognostic significance in septic 
patients. Several studies have shown that 
administration of ATIII in patients with sepsis related 
DIC is effective in shortening the duration of DIC.16 
Measurement of plasma ATIII and, especially, PC 
levels may facilitate the recognition of sepsis and may 
have a prognostic value. 17 
Kountchev et al. showed that six hours after the bolus 
administration of antithrombin, plasma levels of D-
dimer, as a marker for the generation of fibrin, was 
lower in virtually all patients. 18 These data come on 
top of recent additional analyses on the use of 
antithrombin concentrate in patients with severe sepsis 
and may form a new foundation for the further 
evaluation of this compound in prospective clinical 
studies. 
A global improvement in coagulation markers was 
observed in survivors as compared with 
nonsurvivors.19Markers of ongoing thrombin 
generation improved more rapidly in survivors than in 
nonsurvivors over time. Lorente and coworkers13 
previously showed a similar difference in TAT trend 
in survivors compared with nonsurvivors at day 7. 
The prothrombotic host response to outcome observed 
in this study is consistent with data reported by Gando 
and co-workers  indicating that tissue factor antigen 
levels positively correlated with the number of 
dysfunctional organs. 20 Higher levels of the 
anticoagulant factors protein C, protein S, and 
antithrombin in placebo survivors than in 
nonsurvivors at baseline, and the statistically 
significantly higher levels over time during the course 
of the disease, confirm previous observations from 
smaller studies.21 Survivors exhibited greater 
normalization of fibrinolytic potential than did 
nonsurvivors, as indicated by lower levels of 
Plasminogen Activator Inhibitor (PAI)-1 and greater 
increases in plasminogen levels with time. Hesselvik 
and co-workers previously showed an association 
between higher PAI-1 levels and mortality from 
sepsis.22  
Conclusion 
Bad prognosis group of neonates with sepsis had 
significantly reduced Anti-thrombin III levels. Hence, 
antithrombin III can be a potential indicator of 
prognosis in neonatal sepsis.  
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